TLIK Stock Overview
Engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arzneiwerk AG VIDA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.74 |
| 52 Week High | €1.79 |
| 52 Week Low | €0.74 |
| Beta | 0.59 |
| 11 Month Change | -12.35% |
| 3 Month Change | -16.29% |
| 1 Year Change | -42.25% |
| 33 Year Change | -70.67% |
| 5 Year Change | -28.37% |
| Change since IPO | -99.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLIK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -12.4% | -1.9% | -1.8% |
| 1Y | -42.2% | 24.7% | 13.6% |
Return vs Industry: TLIK underperformed the German Healthcare industry which returned 24.7% over the past year.
Return vs Market: TLIK underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| TLIK volatility | |
|---|---|
| TLIK Average Weekly Movement | 6.3% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TLIK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TLIK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 39 | Sascha Knoche | www.arzneiwerk.ag |
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company is based in Berlin, Germany.
Arzneiwerk AG VIDA Fundamentals Summary
| TLIK fundamental statistics | |
|---|---|
| Market cap | €5.11m |
| Earnings (TTM) | -€2.64m |
| Revenue (TTM) | €59.71m |
0.1x
P/S Ratio-1.9x
P/E RatioIs TLIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIK income statement (TTM) | |
|---|---|
| Revenue | €59.71m |
| Cost of Revenue | €56.19m |
| Gross Profit | €3.52m |
| Other Expenses | €6.16m |
| Earnings | -€2.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 5.89% |
| Net Profit Margin | -4.43% |
| Debt/Equity Ratio | -173.8% |
How did TLIK perform over the long term?
See historical performance and comparison